Valuation: Indivior PLC

Market Cap 382.95Cr 340.41Cr 315.51Cr 287.06Cr 541.7Cr 36TCr 550.38Cr 3.79TCr 1.49TCr 19TCr 1.44TCr 1.41TCr 60TCr P/E 2026 *
8.72x
P/E 2027 * 7.9x
Enterprise Value 381.7Cr 339.3Cr 314.48Cr 286.13Cr 539.93Cr 36TCr 548.59Cr 3.78TCr 1.48TCr 19TCr 1.43TCr 1.4TCr 60TCr EV / Sales 2026 *
2.87x
EV / Sales 2027 * 2.33x
Free-Float
98.2%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
-1.82%-1.64% - - 382.95Cr
+0.43%+6.59%+53.41%+103.85% 1,12000Cr
+0.90%-2.25%+33.02%+62.23% 62TCr
+0.71%+3.24%+25.81%+93.86% 50TCr
-0.13%+5.98%+32.91%+50.39% 37TCr
+0.52%+0.24%+73.92%+40.15% 36TCr
-0.95%+4.70%+19.51%+43.00% 29TCr
-1.98%+3.73%-0.86%+13.43% 26TCr
-0.35%+4.25%+46.21%+50.76% 23TCr
-0.75%+3.32%+32.53%+97.21% 19TCr
Average -0.34%+3.61%+35.16%+61.65% 43.79TCr
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%

Financials

2026 *2027 *
Net sales 133.2Cr 118.4Cr 109.74Cr 100Cr 188.41Cr 13TCr 191.43Cr 1.32TCr 517.19Cr 6.6TCr 499.89Cr 489.24Cr 21TCr 139.95Cr 124.4Cr 115.31Cr 104.91Cr 197.97Cr 13TCr 201.14Cr 1.39TCr 543.42Cr 6.93TCr 525.24Cr 514.06Cr 22TCr
Net income 47Cr 42Cr 39Cr 36Cr 67Cr 4.5TCr 68Cr 469.68Cr 184.15Cr 2.35TCr 177.99Cr 174.2Cr 7.49TCr 53Cr 47Cr 44Cr 40Cr 75Cr 5.03TCr 76Cr 524.85Cr 205.78Cr 2.62TCr 198.9Cr 194.66Cr 8.37TCr
Net Debt -1.25Cr -1.11Cr -1.03Cr -93.7L -1.77Cr -118.63Cr -1.8Cr -12Cr -4.85Cr -62Cr -4.69Cr -4.59Cr -197.35Cr -57Cr -51Cr -47Cr -43Cr -81Cr -5.41TCr -82Cr -564.49Cr -221.33Cr -2.82TCr -213.92Cr -209.37Cr -9TCr
Logo Indivior PLC
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
833
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Indivior PLC